Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.

Ito K, Elkin E, Blinder V, Keating N, Choudhry N.

Cancer. 2013 Jul 1;119(13):2494-502. doi: 10.1002/cncr.28084. Epub 2013 Apr 23.

PMID:
23775433
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.

PMID:
18285564
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

Ann Intern Med. 2005 Jul 19;143(2):89-99.

PMID:
16027450
[PubMed - indexed for MEDLINE]
4.

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

Ito K, Blinder VS, Elkin EB.

J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27.

PMID:
22370313
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

PMID:
16834524
[PubMed - indexed for MEDLINE]
Free Article
6.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID:
17610808
[PubMed - indexed for MEDLINE]
Free Article
7.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.

Clin Breast Cancer. 2007 Jun;7(8):608-18.

PMID:
17592673
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.

Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC.

Value Health. 2007 Sep-Oct;10(5):367-76.

PMID:
17888101
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.

Risebrough NA, Verma S, Trudeau M, Mittmann N.

Cancer. 2007 Aug 1;110(3):499-508.

PMID:
17592825
[PubMed - indexed for MEDLINE]
Free Article
10.

Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.

Riley GF, Warren JL, Harlan LC, Blackwell SA.

Medicare Medicaid Res Rev. 2011 Dec 13;1(4). doi: 10.5600/mmrr.001.04.a04.

PMID:
22340780
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
[PubMed - indexed for MEDLINE]
12.
13.

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.

Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA.

Cancer. 2007 Aug 1;110(3):489-98.

PMID:
17592827
[PubMed - indexed for MEDLINE]
Free Article
14.
15.

[Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].

Macedo A, Monteiro I, Andrade S, Cirrincione A, Ray J.

Acta Med Port. 2010 May-Jun;23(3):475-82. Epub 2010 Jun 14. Review. Portuguese.

PMID:
20654267
[PubMed - indexed for MEDLINE]
Free Article
16.

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

Skedgel C, Rayson D, Dewar R, Younis T.

Breast Cancer Res Treat. 2007 Mar;101(3):325-33. Epub 2006 Aug 2.

PMID:
16897433
[PubMed - indexed for MEDLINE]
17.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Hall PS, McCabe C, Stein RC, Cameron D.

J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.

PMID:
22138097
[PubMed - indexed for MEDLINE]
Free Article
18.

Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

Goedken AM, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.

PMID:
20511109
[PubMed - indexed for MEDLINE]
19.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.

Delea TE, El-Ouagari K, Karnon J, Sofrygin O.

Breast Cancer Res Treat. 2008 Apr;108(3):375-87. Epub 2007 Jul 26.

PMID:
17653859
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk